A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results

British Journal of Haematology

Volumn 102, Issue 2, 1998, Pages 495-502

  Cunningham, David ^a   Powles, Ray ^a,c   Malpas, James ^b   Raje, Noopur ^a   Milan, Sarah ^a   Viner, Christine ^a   Montes, Anna ^a   Hickish, Tamas ^a   Nicolson, Marianne ^a   Johnson, Paul ^b   Treleaven, Jennifer ^a   Raymond, Julian ^a   Gore, Martin ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Autologous transplantation; Interferon maintenance; Myeloma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; MELPHALAN; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; MULTIPLE MYELOMA; MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; LONG-TERM CARE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 7344264989     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00795.x     Document Type: Article

References (33)

1. Alexanian, R., Haut, A., Khan, A.U., Lane, M., McKelvey, E.M., Migliore, P.J. Stuckey, W.J. & Wilson, H.E. (1969) Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. Journal of the American Medical Association, 208, 1680-1685.
2. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective randomized trial of autologous hone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
3. Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. & Laurent, G. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
4. Bergsagel, D.E., Haas, R.H. & Messner, H.A. (1986) Interferon alfa-2b in the treatment chronic granulocytic leukemia. Seminars in Oncology, 13, (Suppl. 2), 29-54.
5. Blade, J., San Miguel, J.F., Alcala, A. Maldonado, J., Sanz, M.A., Garcia-Conde, J., Moro, M.J., Alonso, C., Besalduch, J., Zubizarreta, A., Besses, C., Gonzallez-Brito, G., Hernandez-Martin, J., Fernandez-Calvo, J., Rubio, D., Ortega, F., Jimenez, R., Colominas, P., Faura, M.V., Font, L., Tortosa, J., Domingo, A., Fontanillas, N., Rozman, C. & Estape, J. (1995) Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisolone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. Journal of Clinical Oncology, 11, 1165-1171.
6. Borden, E.C. & Ball, L.A., (1981) Interferons: biochemical, cell growth inhibitory and immunological effects. Progress in Hematology, 12, 299-339.
7. Browman, G.E., Rubin, S., Walker, L., Sicheri, D., Berch, A., O'Reilly, S., Wilson, K., Barr, R., Johnston, D., James, K., Zee, B.C. & Pater, J. (1994) Interferonα-2b (IFN) maintenance therapy prolongs progression free and overall survival in plasma cell myeloma (PCM): results of a randomized trial. Proceedings of the American Society for Clinical Oncology, 13, 408 (abstract 1491).
8. Chronic Leukemia-Myeloma Task Force. National Cancer Institute. (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemotherapy Reports, 4, 145-158.
9. Cooper, M.R., Dear, K., McIntyre, R., Ozer, H., Ellerton, J., Canellos, G., Bernhardt, B., Duggan, D., Faragher, D. & Schiffer, C. (1995) A randomized clinical trial comparing melphalan/prednisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 11, 155-160.
10. Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicholson, M., Meldrum, M., Viner, C., Milan, S., Selby, P.J., Norman, A., Raymond, J. & Powles, R. (1994a) High-dose melphalan for multiple myeloma: long-term follow-up data. Journal of Clinical Oncology, 12, 764-768.
11. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleaven, J., Viner, C., Malpas, J., Slevin, M., Findlay, M., Raymond, J. & Gore, M.E. (1994b) High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Journal of Clinical Oncology, 12, 759-763.
12. Cunningham, D., Powles, R., Malpas, J., Milan, S., Meldrum, M., Viner, C., Montes, A., Hickish., T., Nicolson, M., Johnson, P., Mansi, J., Treleaven, J., Raymond, J. & Gore, M.E. (1993) A randomized trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. American Society of Clinical Oncology Abstracts, 12, 364.
13. Drayson, M.T., Chapman, C.E., Olujohungbe, A.B., Dunn, J.A. & MacLennan, I.C.M. (1997) The MRC randomised trial of α2b-interferon in first plateau phase of multiple myeloma. In: Proceedings of the VI International Workshop on Multiple Myeloma, Boston, Mass.
14. Gore, M.E., Selby, P.J., Viner, C., Clark, P.I., Meldrum, M., Millar, B., Bell, J., Maitland, J.A., Milan, S., Judson, I.R., Zuiable, A., Tillyer, C., Slevin, M., Malpas, J.S. & McElwain, T.J (1989) Intensive treatment for multiple myeloma and criteria for complete remission. Lancet, ii, 879-882.
15. Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334-342.
16. Harousseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Caillot, D., Boasson, M., Abgrall, J.F., Facon, T., Linassier, C., Cahn, J.Y., Larny, T., Troussard, X., Grabecos, N., Pignon, B., Auzanneau, G. & Bataille, R. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 3077-3085.
17. Hjorth, M., Westin, J., Dahl, I.M.S., Gimsin, P., Hippe, E., Lomvik, J., Nielson, J.L., Lofvenberg, E., Palve, L.P., Rodjer, S., Tolstad, I., Turesson, I., Wisloff, F. & Zadar, G. (1996) Interferon-α2b added to melphalan-prednisolone for initial and maintenance therapy in a multiple myeloma: a randomized, controlled trial. Annals of Internal Medicine, 124, 212-222.
18. Jagannath, S., Vesole, D.H., Glenn, L., Crowley, J. & Barlogie, B. (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 80, 1666-1672.
19. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
20. Ludwig, H. (1997) Role of α-interferon in myeloma. In: Proceedings of the VI International Myeloma Workshop, Boston, Mass.
21. Ludwig, H., Cohen, A.M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Gunczler, P., Seewann, H.L., Schuller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies. Annals of Oncology, 6, 467-476.
22. MacLennan, I.C.M., Chapman, C., Dunn, J. & Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, 200-205.
23. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Dammacco, F. & Pileri, A. (1990) Maintenance treatment with recombinant alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 322, 1430-1434.
24. McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma cell leukemia and myeloma, Lancet, ii, 822-824.
25. Mellstedt, H., Ahre, A., Bjorkholm, M., Holm, G., Johansson, B. & Strander, H. (1979) Interferon therapy in myelomatosis. Lancet, i, 245-247.
26. Osterborg, A., Ahre, A., Bjorkholm, M., Bjoreman, M., Brenning, G., Gahrton, G., Gyllenhammar, H., Johansson, B., Juliusson, G. & Jarnmark, M. (1989) Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisolone in the treatment of multiple myeloma stage III: a randomized study from MGCS, European Journal of Haemotology, 43, 54-62.
27. Osterborg, A., Bjorkholm, M., Bjorman, M., Brenning, G., Carlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., Hast, R., Johansson, B., Juliusson, G., Janmark, M., Kimby, E., Lerner, R., Linder, O., Merk, K., Nilsson, B., Ohrling, M., Paul, C., Simonsson, B., Smedmyr, B., Svedmyr, E., Stalfelt, A.M., Strander, H., Uden, A.M., Osby, E. & Mellstedt, H. (1993) Natural interferon-alpha in combination with melphalan/prednisolone versus melphalan/prednisolone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood, 81, 1428-1434.
28. Peest, D., Deicher, H., Coldwey, R., Leo, R., Bartl, R., Bartels, H., Braun, H.J., Fett, W., Fischer, J.T. & Gobel, B. (1995) A comparison of polychemotherapy and melphalan prednisolone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. European Journal of Cancer, 31, 146-151.
29. Peto, R. & Peto, J. (1972) Asymptomatically efficient invariant procedures. Journal of the Royal Statistcal Society A, 135, 185-206.
30. Powles, R.L., Raje, N.S., Cunningham, D., Malpas, J., Milan, S., Horton, C., Mehta, J., Singhal, S., Viner, C. & Treleaven, J. (1995) Maintenance therapy for remission in myeloma with Intron A following high dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells (Daytona), 13, 114-117.
31. Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, Glucocortcoids, and Interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study, Journal of Clinical Oncology, 12, 2405-2414.
32. Samid, D., Flessate, D.M., Greene, J.J., Chang, E.H. & Friedman, R.M. (1985) Mechanisms of antioncogenic activity of interferon. The 2-5A System: Molecular and Clinical Aspects of the Interferon-regulated Pathway (ed. by B. R. G. William and R. H. Silverman), pp. 203-209. Alan R. Liss, New York.
33. Westin, J., Rodjer, S., Turesson, I., Cortelezzi, A., Hjorth, M. & Zador, G. (1995) Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. British Journal of Haematology, 89, 561-568.